Starpharma today released its annual report and financial results for the year ended 30 June 2014.

Starpharma CEO Jackie Fairley joins The Business’ Presenter Ticky Fullerton to discuss TGA approval of a VivaGel coated condom in depth, revisiting the shorting issue covered prior on the show, the benefits of the announcement to broader Australian innovation, and a business update on Starpharma’s DEP docetaxel drug development. 

Glamour UK, a magazine for women with a UK online readership of 3.38 million, covered the announcement that Starpharma had received TGA approval for VivaGel coated condoms. 

The Washington Times’ picked up the announcement that Starpharma and Ansell have received TGA approval of the VivaGel coated condom from The Daily Mail UK.  

In an article that goes into a significant amount of scientific detail for a mainstream news publication, the Daily Mail covered the TGA of VivaGel coated condoms announcement. 

Elite Daily, a widely read US based publication targeted at generation Y, reported that VivaGel kills up to 99% of HIV and Herpes following the announce TGA approval of VivaGel coated condoms in Australia. 

The ABC reported that while condoms are the best method of sexual protection available, they are currently not 100% effective in preventing either pregnancy or sexually transmitted infections and so anything you can do to reduce the number of virus particles by inactivating them with a substance like VivaGel would reduce that overall viral load.

Following the announcement that Starpharma received TGA approval for VivaGel coated condoms in Australia, the AFR reported on the significance of the deal for Australian innovation.